検索結果

. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Japan as an option of RET-700, effect...

. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Japan as an option of RET-700, effect...

Quality Policies | About Senju | SENJU Pharmaceutical

We will set the following "Quality Policies" and continue to be a "Good Company" by encouraging cooperation among all employees and providing high-quality products for "realiz...

OTC Products, etc. | Products | SENJU Pharmaceutical

Inquiries are not accepted in a language other than Japanese in principle. Please kindly understand the situation that the inquiries by telephone must use Japanese only. Translated from the Japanese p...

tical Co., Ltd. Senju announces initiation of Phase III Clinical Trials in Japan for “SJP-0008” for the treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osak...